Life Sciences

Lessons from the supply chain

06/2022
lessons from the supply chain

The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds. But, behind the headlines, how is the pandemic affecting attitudes to risk

From governments to corporates, the importance of a diversified supply chain has been a big lesson of the pandemic. At the start, the global supply chain was tested as governments around the world urgently tried to buy personal protective equipment (PPE), test kits and other medical devices. With various countries limiting exports of products from drugs to PPE, the tension between national priorities and globalised free markets has become abundantly clear.

For governments, ways to manage health security more closely and bring production of life science products closer to home will be a big question as the dust settles on this pandemic. For life science companies, a focus on local supply and diversification are two key themes in corporate risk mitigation efforts, after experiencing first-hand the risks posed to their supply chains by government interventions, lockdowns and competition for resources.

With attention shifting to vaccines, the downstream supply chain is now where some of the most significant risks reside. With some vaccines needing to be stored at very cold temperatures, the pressure is on within the supply chain. If temperatures, among other parameters such as vibration and humidity, are not properly maintained when drugs are transported, it can lead to batches being thrown away.

Read the “Lessons from the Supply Chain” report to get an insight into how sourcing challenges during the pandemic is changing attitudes to risk in the supply chain, and ultimately changing the shape of the supply chain itself.

Key takeaways

  • Tensions over vaccine supply timelines emphasize the importance of drafting clear contracts.
  • Claims arise when pharma products fall outside of set parameters, such as temperature limits, during transit.
  • If a shipment’s value includes research and development (R&D) costs, liability can become contentious.
  • From governments to corporates, diversification of suppliers and near-shoring are being discussed.
Download

Lessons from the supply chain

Read more reports in the ‘Life Science in the era of pandemics’ series:

Insights and Expertise

We keep you informed — and your business protected — with these helpful articles.
a doctor using tablet
The great telehealth experiment
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
medical devices
Making medical devices during a pandemic
How has the coronavirus pandemic affected the risk profile of medical device manufacturing?
medical equipment
3 big questions with life science expert Travis McIntosh
What do the new COVID-19 vaccines mean to insurers and the Life Science industry at large? How has COVID-19 affected Life Science companies?
abstract virus
Emerging risks in COVID-19 clinical trials
As the scientific community races to respond to COVID-19, best practice is slipping in clinical trials. What trade-offs are being made and who is liable?
bright dna spiral
Fighting COVID-19 with genomics
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare
holding lame and lamelle in front of a microscope
Life Science in the era of pandemics
Two years into the pandemic, we consider its impact on the life science sector and how the risk landscape is evolving as the industry builds on the progress it has made.

Have a question or need more information?

Contact us to find out how we can help you get covered against potential risks.